3
Announcements
Trials
Browse
Landscape
Status
Approved for marketing
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Hairy Cell
1
Leukemia
1
Interventions
immunotoxin HA22
3
Cyclophosphamide
2
trametinib
1
polatuzumab vedotin
1
pembrolizumab
1
ontuxizumab
1
ibrutinib
1
fludarabine
1
dabrafenib
1
brexucabtagene autoleucel
1
acalabrutinib
1
Trazodone
1
Rituximab
1
Prednisone
1
PLX8394
1
Lenalidomide
1
HA 22
1
Fentanyl
1
Doxorubicin
1
AGS67E
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Leukemia, Hairy Cell
×
HA 22
×
Clear all
NCT03501615
2020-06-29
MOXE
AstraZeneca
Approved for marketing